On November 1, 2019, the LGS Foundation convened the first patient-focused drug development meeting (PFDD) for the DEEs (developmental and epileptic encephalopathies) including Lennox-Gastaut Syndrome in College Park. Over 100 people ranging from patients, caregivers, FDA representatives, pharmaceutical companies, device…
Our 2021 Research Grant Cycle: CLOSED The LGS Foundation’s seed grant program awards one-year research grants up to $30,000 and two-year grants up to$50,000 (the LGS Foundation does not permit indirect costs) to young investigators, physician residents, and clinicians who…
The following are key publications in LGS that are open access and free of charge. 2019: Seizure burden in seizure early-life epilepsy: Perspectives from parents (Berg et al. Epilepsia Open, 2019) The direct cost of seizure events in severe childhood-onset…
What is a Clinical Trial? Clinical Trial Phases Phase I: Researchers test a new drug or treatment in a small group of healthy volunteers and/or people with the disease for the first time to evaluate its safety, determine a safe…
The LGS Foundation is organizing the first-ever Meeting of the Minds professional conference to find disease-modifying therapies and cures for LGS. This two-day Virtual Conference will bring together patients, families, doctors, researchers, industry partners, and advocacy organizations to discuss progress…
Meet Our 2021 LGS Foundation Research Award Winner Dr. Jennifer Kearney, Northwestern University RNA Modulation in KCNB1 Model of LGS Lennox-Gastaut Syndrome (LGS) is a severe pediatric epilepsy syndrome that includes a characteristic EEG pattern, some degree of cognitive impairment, and…
“Together we can change the future for those with Lennox-Gastaut Syndrome.” What is LGS? Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. Children with LGS experience frequent, uncontrollable seizures and…
